<DOC>
	<DOCNO>NCT01065532</DOCNO>
	<brief_summary>Different heal response treatment bare metal stent restenosis implantation everolimus-eluting Xience V stent ( Abbott Vascular ) versus use paclitaxel-eluting SeQuent Please balloon ( BBraun ) : optical coherence tomography study . A prospective , single-centre , randomized clinical trial clinical , angiographic OCT follow-up 9 month .</brief_summary>
	<brief_title>SEDUCE OCT Study Coronary Artery rEstenosis : Optical Coherence Tomography ( OCT ) Study</brief_title>
	<detailed_description>Background : The optimal treatment bare metal stent restenosis ( implantation drug-eluting stent , simple balloon dilatation , CABG ) still define . The used option nowadays implantation drug-eluting stent ( DES ) . However , procedure implies application double metal layer vessel wall , link delayed healing . Furthermore might high risk malapposition strut bare metal newly implant drug-eluting stent . These phenomenon 's might give rise increase risk stent thrombosis patient population . Recently , drug-eluting balloon ( DEB ) propose new treatment strategy bare metal stent restenosis . The initial result technique look promise . Aim : To compare heal process treatment BMS ISR balloon dilatation use DEB versus implantation DES . Methods : 50 patient BMS restenosis ( SVG bifurcation lesion exclude ) randomize two treatment group : SeQuent Please drug-eluting balloon dilatation ( group I ) versus implantation everolimus-eluting Xience V stent ( group II ) . At 9 month , control angiography OCT pullback treat segment plan .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Patient old 18 year 2. write informed consent available 3. patient eligible percutaneous coronary intervention 4. patient single multiple restenotic lesion ( ) previously stented area coronary artery ( irrelevant whether BMS DES ) 5 . Target reference vessel diameter measure QCA : 24 mm 6 . Target lesion length measure QCA &lt; 24 mm 7 . Target lesion stenosis measure QCA : &gt; 70 % &lt; 100 % 8 . Patients willing provide write informed consent prior participation willing able participate followup evaluation . 1 . Left ventricular ejection fraction &lt; 30 % 2 . Impaired renal function ( serum creatinine &gt; 2.0 mg/dl ) 3 . Target lesion locate bifurcation 4 . Previous and/or plan brachytherapy target vessel 5 . Lesion leave main trunk &gt; 50 % , unprotected 6 . Known allergy antiplatelet , anticoagulation therapy , contrast medium , paclitaxel everolimus 7 . Pregnant and/or breastfeed female female intend become pregnant ( pregnancy test require ) 8 . Patients life expectancy le one year 9 . Patients intend major surgical intervention within 6 month enrolment study . 10 . Patient currently enrol investigational device drug trial 11 . Patient able willing adhere followup visit 12 . Patients previously participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Restenosis</keyword>
	<keyword>PCI</keyword>
	<keyword>Drug-eluting stent</keyword>
	<keyword>Drug-eluting balloon</keyword>
	<keyword>Optical Coherence Tomography</keyword>
</DOC>